Figure 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer door Erwei Zeng (14958443)

Onderwerpen:

Figure 2 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer door Erwei Zeng (14958443)

Onderwerpen:

Figure 3 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer door Erwei Zeng (14958443)

Onderwerpen:

Table 1 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer door Erwei Zeng (14958443)

Onderwerpen:

Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer door Erwei Zeng (14958443)

Onderwerpen:

Figure 3 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia door Alba L. Combita (22677298)

Onderwerpen:

Figure 2 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia door Alba L. Combita (22677298)

Onderwerpen:

Figure 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia door Alba L. Combita (22677298)

Onderwerpen:

Figure 5 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia door Alba L. Combita (22677298)

Onderwerpen:

Supplementary Tables S1-S12 from Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer door Achal Patel (5853731)

Onderwerpen:

Figure 4 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia door Alba L. Combita (22677298)

Onderwerpen:

Table 1 from Reduction in Vaccine HPV Type Infections in a Young Women Group (18–25 Years) Five Years after HPV Vaccine Introduction in Colombia door Alba L. Combita (22677298)

Onderwerpen:

Table S5 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection door Nina Rao (15321199)

Onderwerpen:

Table S4 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection door Nina Rao (15321199)

Onderwerpen:

Table S2 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection door Nina Rao (15321199)

Onderwerpen:

Table S7 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection door Nina Rao (15321199)

Onderwerpen:

Table S3 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection door Nina Rao (15321199)

Onderwerpen:

Table S1 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection door Nina Rao (15321199)

Onderwerpen:

Table S6 from Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection door Nina Rao (15321199)

Onderwerpen:

Characterization of a Novel Porcine Circovirus Type 2a Sequence and Anti-Viral Evaluation of Matrine and Sanguinarine Combined with Network Pharmacology and Molecular Docking door WENTING Qiao (22587494)

Onderwerpen: “…Veterinary epidemiology…”